Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting

AbbVie236 enrolled

Overview

This study will assess the effects of adalimumab treatment in moderate to severe Hidradenitis Suppurativa (HS) patients in the real world setting. The objectives of this study are to estimate the effectiveness of adalimumab treatment on disease severity, to estimate the impact of adalimumab treatment on patients' quality of life, psychological effect, work productivity and healthcare resource utilization and to describe treatment practices over the study period.

Study Type

OBSERVATIONAL

Enrollment

236

Conditions

Hidradenitis Suppurativa

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of moderate to severe Hidradenitis Suppurativa * The decision to treat with adalimumab (Humira) is made by the physician in accordance with the local label (Summary of Product Characteristics; product label) prior to any decision to approach the participant to participate in this study * Participants willing to be involved in the study and to sign patient authorization form to use and disclose personal health information (or informed consent, where applicable) Exclusion Criteria: * Participants in a clinical interventional study * Participants treated with adalimumab prior to baseline visit

Locations (83)

Outcomes

Primary Outcomes

Proportion of participants with moderate to severe Hidradenitis Suppurativa (HS) who achieve a clinical response

Clinical response is evaluated by using the Hidradenitis Suppurativa clinical response measure (HiSCR)

Time frame: At Week 12

Secondary Outcomes

Proportion of participants with moderate to severe HS who achieve a clinical response

Clinical response is evaluated by using the Hidradenitis Suppurativa clinical response measure (HiSCR)

Time frame: Up to week 52

Changes from baseline in Dermatology Quality of Life Index (DLQI)

Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired.

Time frame: From Week 0 to Week 52

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Krankenanstalt Rudolfstiftung /ID# 166804

Vienna, State of Vienna, Austria

LKH-Univ. Klinikum Graz /ID# 166802

Graz, Austria

Klinikum Wels - Grieskirchen /ID# 158017

Wels, Austria

UZ Brussel /ID# 154218

Jette, Brussels Capital, Belgium

Cliniques Universitaires Saint Luc /ID# 154217

Woluwe-Saint-Lambert, Brussels Capital, Belgium

CHU de Liege /ID# 154220

Liège, Liege, Belgium

UZ Gent /ID# 154221

Ghent, Oost-Vlaanderen, Belgium

CLIDERM Bruxelles /ID# 154232

Anderlecht, Belgium

PP Anderlecht /ID# 154230

Anderlecht, Belgium

CHIREC- City Clinic Louise /ID# 154227

Brussels, Belgium

...and 73 more locations